| Title |
Precision Oncology for Cancer Immunotherapies in Early-Phase Clinical Trials
|
|---|---|
| Published in |
Targeted Oncology, October 2019
|
| DOI | 10.1007/s11523-019-00678-w |
| Pubmed ID | |
| Authors |
Xavier Paliard, Olivier Rixe |
X Demographics
The data shown below were collected from the profiles of 10 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 3 | 30% |
| Brazil | 1 | 10% |
| Mexico | 1 | 10% |
| United States | 1 | 10% |
| Unknown | 4 | 40% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 40% |
| Scientists | 3 | 30% |
| Practitioners (doctors, other healthcare professionals) | 2 | 20% |
| Science communicators (journalists, bloggers, editors) | 1 | 10% |
Mendeley readers
The data shown below were compiled from readership statistics for 18 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 18 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 5 | 28% |
| Other | 4 | 22% |
| Student > Ph. D. Student | 2 | 11% |
| Student > Master | 2 | 11% |
| Professor | 1 | 6% |
| Other | 2 | 11% |
| Unknown | 2 | 11% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 28% |
| Medicine and Dentistry | 4 | 22% |
| Biochemistry, Genetics and Molecular Biology | 2 | 11% |
| Immunology and Microbiology | 2 | 11% |
| Engineering | 1 | 6% |
| Other | 0 | 0% |
| Unknown | 4 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 July 2020.
All research outputs
#5,777,087
of 23,511,526 outputs
Outputs from Targeted Oncology
#77
of 565 outputs
Outputs of similar age
#102,438
of 353,710 outputs
Outputs of similar age from Targeted Oncology
#5
of 21 outputs
Altmetric has tracked 23,511,526 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 565 research outputs from this source. They receive a mean Attention Score of 2.9. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 353,710 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.